You have free access to this content

Cancer

Cover image for Cancer

15 April 1997

Volume 79, Issue 8

Pages 1453–1640

  1. Editorials

    1. Top of page
    2. Editorials
    3. Commentaries
    4. Original Articles
    1. Counterpoint

      You have free access to this content
      Lumpectomy margins and much more (pages 1453–1458)

      Edwin R. Fisher

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1453::AID-CNCR1>3.0.CO;2-C

      This counterpoint presents considerations related to the role of lumpectomy in the treatment of breast carcinoma and the nature of its sequela of ipsilateral breast tumor recurrence.

      See also pages 1459–1460 and 1568–1473

    2. Reply to Counterpoint

      You have free access to this content
      Lumpectomy margins and much more—reply (pages 1459–1460)

      Anthony J. Guidi, James L. Connolly, Jay R. Harris and Stuart J. Schnitt

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1459::AID-CNCR2>3.0.CO;2-6

      See also pages 14553–1458 and 1568–1573

  2. Commentaries

    1. Top of page
    2. Editorials
    3. Commentaries
    4. Original Articles
    1. You have free access to this content
      Autoantibodies to tyrosinase : The bridge between melanoma and vitiligo (pages 1461–1464)

      Pnina Fishman, Ofer Merimski, Ehud Baharav and Yehuda Shoenfeld

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1461::AID-CNCR3>3.0.CO;2-E

      • original image

      Antityrosinase antibodies are found in the sera of patients with diffuse vitiligo and in the sera of patients with metastatic melanoma and may play an important role in the follow-up and treatment of these patients.

  3. Original Articles

    1. Top of page
    2. Editorials
    3. Commentaries
    4. Original Articles
    1. Anatomic Site

      You have free access to this content
      Salivary gland tumors among atomic bomb survivors, 1950-1987 (pages 1465–1475)

      Takashi Saku, Yuzo Hayashi, Osamu Takahara, Hiroo Matsuura, Masayoshi Tokunaga, Shoji Tokuoka, Midori Soda, Kiyohiko Mabuchi and Charles E. Land

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1465::AID-CNCR4>3.0.CO;2-A

      • original image
      • original image
      • original image
      • original image

      In a cohort study of Japanese atomic bomb survivors, radiation exposure was significantly associated with malignant tumors of the salivary glands, especially mucoepidermoid carcinoma, and a particular type of benign tumor, Warthin's tumor.

    2. You have free access to this content
      Atypical carcinoid of the esophagus : A case report and review of the literature (pages 1476–1481)

      Guy M. Lindberg, Kyle H. Molberg, M. Frank Vuitch and Jorge Albores-Saavedra

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1476::AID-CNCR5>3.0.CO;2-9

      • original image
      • original image
      • original image
      • original image
      • original image

      The authors report an atypical carcinoid tumor of the upper esophagus. On review of the literature, 13 cases of esophageal carcinoid tumors were discovered; their clinicopathologic features are summarized.

    3. You have free access to this content
      Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue (pages 1482–1486)

      Erwin Schauenstein, Hans Rabl, Waltraud Steinschifter, Carola Hirschmann, Willibald Estelberger and Konrad Schauenstein

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1482::AID-CNCR6>3.0.CO;2-D

      • original image
      • original image
      • original image

      As previously shown with other malignancies, the occurrence of colorectal carcinoma is associated with a selective decrease in serum immunoglobulin G1, representing an indirect tumor marker with 88% specificity and 74% sensitivity.

    4. You have free access to this content
      Lack of promotion of colon carcinogenesis by high-oleic safflower oil (pages 1487–1493)

      Masazumi Takeshita, Hiroshi Ueda, Komei Shirabe, Yasunori Higuchi and Satoshi Yoshida

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1487::AID-CNCR7>3.0.CO;2-8

      • original image
      • original image

      High-oleic (monounsaturated) safflower oil did not enhance colon carcinogenesis induced by 1,2-dimethylhydrazine in ICR mice, even when they were fed a high-fat diet.

    5. You have free access to this content
      The long term efficacy of glycyrrhizin in chronic hepatitis C patients (pages 1494–1500)

      Yasuji Arase, Kenji Ikeda, Naoya Murashima, Kazuaki Chayama, Akihito Tsubota, Isao Koida, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi and Hiromitsu Kumada

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B

      • original image
      • original image
      • original image
      • original image
      • original image

      Normalization of alanine aminotransferase by long term administration of Stronger Neo-Minophagen C, a Japanese medicine commonly administered to patients with chronic hepatitis C, helps protect patients against hepatocarcinogenesis.

    6. You have free access to this content
      Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection (pages 1501–1508)

      Maurizio Pompili, Gian Ludovico Rapaccini, Francescantonio de Luca, Eugenio Caturelli, Antonio Astone, Domenico Angelo Siena, Maria Rosaria Villani, Anna Grattagliano, Augusto Cedrone and Giovanni Gasbarrini

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1501::AID-CNCR9>3.0.CO;2-D

      • original image
      • original image
      • original image
      • original image
      • original image

      Cirrhotic patients with a single hepatocellular carcinoma <5 cm treated by percutaneous ethanol injection showed a high cumulative 4-year intrahepatic recurrence of the tumor (62%). The risk of tumor recurrence in liver segments that are different from that of the first neoplasm was significantly increased in patients with serum levels of alpha-fetoprotein > 25 ng/mL and 13 ng/mL prior to and 1 month after the treatment, respectively.

    7. You have free access to this content
      Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma (pages 1509–1515)

      Naoki Yamanaka, Tsuneo Tanaka, Wataru Tanaka, Junichi Yamanaka, Chiaki Yasui, Nobukazu Kuroda, Masafumi Takada and Eizo Okamoto

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1509::AID-CNCR10>3.0.CO;2-1

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Patients positive for hepatitis C antibody have a higher rate of intrahepatic recurrence than those positive for hepatitis B surface antigen after curative resection for hepatocellular carcinoma.

    8. You have free access to this content
      Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma (pages 1516–1520)

      Hiroshi Ishii, Shuichi Okada, Koichi Tokuuye, Haruhiko Nose, Takuji Okusaka, Masayoshi Yoshimori, Hiroyasu Nagahama, Minako Sumi, Yoshikazu Kagami and Hiroshi Ikeda

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1516::AID-CNCR11>3.0.CO;2-0

      • original image

      Protracted 5-fluorouracil infusion with concurrent radiotherapy showed moderate activity against locally advanced pancreatic carcinoma and was accompanied by an acceptable toxicity level.

    9. You have free access to this content
      The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia : A comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis (pages 1521–1526)

      Kenji Suzuki, Kanji Nagai, Junji Yoshida, Tomoyuki Yokose, Tetsuro Kodama, Kenro Takahashi, Mitsuyo Nishimura, Hidenori Kawasaki, Michiya Yokozaki and Yutaka Nishiwaki

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1521::AID-CNCR12>3.0.CO;2-#

      • original imageoriginal imageoriginal imageoriginal imageoriginal imageoriginal image
      • original image
      • original image
      • original image
      • original image
      • original image

      The prognosis of patients with lung carcinoma associated with atypical adenomatous hyperplasia (AAH) was compared with that of adenocarcinoma patients with intrapulmonary metastatis (PM). A significant difference was found between these two groups. This result indicates that the morphologic distinction between AAH and PM in well-differentiated adenocarcinoma, especially in bronchioloalveolar carcinoma, is possible in most cases.

    10. You have free access to this content
      Lung carcinoma patients with a family history of cancer and lymphocyte primary chromosome 9 aberrations (pages 1527–1532)

      Xifeng Wu, Bhavana J. Dave, Hong Jiang, Sen Pathak and Margaret R. Spitz

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1527::AID-CNCR13>3.0.CO;2-#

      In this study, patients with lung carcinoma were shown to be more likely than healthy controls to exhibit spontaneous chromosome 9 aberrations in peripheral lymphocyte cultures. Patients with these aberrations were significantly more likely to report a history of lung carcinoma in first-degree relatives.

    11. You have free access to this content
      Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma (pages 1533–1540)

      Tatsuya Yoshimasu, Shinichiro Miyoshi, Shinji Maebeya, Takaomi Suzuma, Toshiya Bessho, Issei Hirai, Hirokazu Tanino, Junji Arimoto and Yasuaki Naito

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1533::AID-CNCR14>3.0.CO;2-Z

      • original image
      • original image
      • original image

      Serum kinetics of carcinoembryonic antigen (CEA) after resection of lung carcinoma were studied. Biologic half-life was not correlated with patient prognosis. Serum CEA level at plateau after surgery and postoperative CEA production were both correlated with recurrence in the early postoperative period.

    12. You have free access to this content
      p53 and MDM2 alterations in osteosarcomas : Correlation with clinicopathologic features and proliferative rate (pages 1541–1547)

      Fulvio Lonardo, Takafumi Ueda, Andrew G. Huvos, John Healey and Marc Ladanyi

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y

      • original image

      MDM2 copy number and p53 protein levels were determined in 83 samples of osteosarcoma. Immunoreactivity for p53 was found in 26.5% and MDM2 amplification in 6.6% of samples, mostly in a mutually exclusive fashion.

    13. You have free access to this content
      Immunosuppressive therapy for hypoplastic myelodysplastic syndrome (pages 1548–1551)

      Douwe H. Biesma, Jan G. van den Tweel and Leo F. Verdonck

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1548::AID-CNCR16>3.0.CO;2-Y

      • original imageoriginal image
      • original image

      Two patients with hypoplastic myelodysplastic syndrome, who had no chromosomal abnormalities and for whom no suitable bone marrow donors were available, were successfully treated with cyclosporin A and antithymocyte globulin as immunosuppressive therapy.

    14. You have free access to this content
      The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia (pages 1552–1560)

      Hiroshi Iwama, Kazuma Ohyashiki, Junko H. Ohyashiki, Shigefumi Hayashi, Ken Kawakubo, Jerry W. Shay and Keisuke Toyama

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1552::AID-CNCR17>3.0.CO;2-X

      • original image
      • original image
      • original image

      Telomere length and telomerase activity were measured in patients with chronic myeloid leukemia. Normal telomere length at the time of diagnosis indicates a subset of patients who may respond favorably to alpha-interferon therapy.

    15. You have free access to this content
      Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma : Results of Eastern Cooperative Oncology Group study E2479 (pages 1561–1567)

      Martin M. Oken, David P. Harrington, Neil Abramson, Robert A. Kyle, William Knospe and John H. Glick

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W

      • original image
      • original image

      In a randomized Phase III trial involving 479 patients, the Eastern Cooperative Oncology Group compared melphalan and prednisone with vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP) as chemotherapy for multiple myeloma. A higher response rate and superior response duration were found with the VBMCP regimen. Survival was not shown to be different by standard log rank comparison of survival curves, but superior 5-year survival was suggested with VBMCP, especially for patients with early-stage disease.

    16. You have free access to this content
      The relationship between shaved margin and inked margin status in breast excision specimens (pages 1568–1573)

      Anthony J. Guidi, James L. Connolly, Jay R. Harris and Stuart J. Schnitt

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1568::AID-CNCR19>3.0.CO;2-W

      • original image

      Two methods for examining the margins of breast reexcision specimens were compared. Many patients with positive shaved margins did not have positive margins when evaluated by the standard inked margin method (i.e., sections taken perpendicular to the inked surface). The clinical implications of a positive shaved margin may not be the same as those of a positive inked margin.

      See also pages 1453–1458 and 1459–1460.

    17. You have free access to this content
      All-trans retinoic acid and interferon-α-2a in patients with metastatic or recurrent carcinoma of the uterine cervix : Clinical and pharmacokinetic studies (pages 1574–1580)

      Scott Wadler, Edward L. Schwartz, Hilda Haynes, Ronalde Rameau, Astrid Quish, John Mandeli, Robert Gallagher, Steven Hallam, Abbie Fields, Gary Goldberg, Frances McGill, Scott Jennings, Robert C. Wallach, Carolyn D. Runowicz and for the New York Gynecologic Oncology Group

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1574::AID-CNCR20>3.0.CO;2-U

      All-trans retinoic acid and interferon were inactive against advanced cervical carcinoma whether delivered on a daily or intermittent schedule. This was not related to induction of metabolism of the retinoid.

    18. You have free access to this content
      K-ras mutations in mucinous ovarian tumors : A clinicopathologic and molecular study of 95 cases (pages 1581–1586)

      Miriam Cuatrecasas, Alberto Villanueva, Xavier Matias-Guiu and Jaime Prat

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T

      • original image
      • original image

      K-ras mutations were detected in 58% of benign, 86% of borderline, and 85% of malignant mucinous ovarian tumors. The coexistence of the K-ras mutations in the benign, borderline, and/or malignant components of the same ovarian tumor suggests that K-ras mutations are early events in mucinous ovarian tumorigenesis.

    19. You have free access to this content
      A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma (pages 1587–1594)

      Lynn D. Kowalski, Anisa I. Kanbour, Fredric V. Price, Sydney D. Finkelstein, Wayne A. Christopherson, Jan C. Seski, Gregory J. Naus, Judith A. Burnham, Amal Kanbour-Shakir and Robert P. Edwards

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1587::AID-CNCR22>3.0.CO;2-T

      • original image
      • original image
      • original image
      • original image
      • original image

      Extraovarian müllerian adenocarcinomas display twice the frequency of HER-2/neu overexpression as primary ovarian carcinomas.

    20. You have free access to this content
      Immunohistochemical expression of π-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate (pages 1595–1599)

      Christopher A. Moskaluk, Paul H. Duray, Kenneth H. Cowan, Marston Linehan and Maria J. Merino

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S

      • original image
      • original image
      • original image

      Glutathione S-transferase is lost during progression of epithelial tumors of the prostate, including prostatic intraepithelial neoplasia. This differs from the findings for many other human tumors.

    21. You have free access to this content
      Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma (pages 1600–1604)

      Alfred I. Neugut, Habibul Ahsan, Eliezer Robinson and Ronald D. Ennis

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1600::AID-CNCR24>3.0.CO;2-0

      Utilizing population-based data from the National Cancer Institute (Surveillance, Epidemiology, and End Results Program), this study found that the risk of bladder carcinoma was elevated 5 years after primary radiation therapy (RT) for prostate carcinoma. By 8 years, the risk had risen to 1.5 times the normal rate. There were no elevations in risk for leukemia or rectal carcinoma after RT for prostate carcinoma.

    22. You have free access to this content
      Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer (pages 1605–1610)

      E. Randolph Broun, Craig R. Nichols, Gary Gize, Kenneth Cornetta, Robert A. Hromas, Brenda Schacht and Lawrence H. Einhorn

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1605::AID-CNCR25>3.0.CO;2-0

      Treatment incorporating brief conventional dose therapy followed by two cycles of high dose therapy resulted in prolonged disease free survival for patients with relapsed testicular germ cell cancer.

    23. You have free access to this content
      Thyroid carcinoma found at parathyroidectomy : Association with primary, secondary, and tertiary hyperparathyroidism (pages 1611–1616)

      Lynn A. Burmeister, Marc Sandberg, Sally E. Carty and Charles G. Watson

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1611::AID-CNCR26>3.0.CO;2-#

      • original image

      In this study, the prevalence of patients with well differentiated thyroid carcinoma found at the time of parathyroidectomy for primary versus secondary and/or tertiary hyperparathyroidism was not significantly different. This suggests that the association between thyroid carcinoma and hyperparathyroidism is coincidental and possibly related to the closer surveillance of the thyroid gland due to parathyroidectomy and often concomitant removal of thyroid tissue.

    24. General Topic

      Bone Marrow Transplantation
      You have free access to this content
      Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation (pages 1617–1622)

      Ulrich Keilholz, Regina Max, Carmen Scheibenbogen, Christian Wüster, Martin Körbling and Rainer Haas

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1617::AID-CNCR27>3.0.CO;2-#

      • original image

      In 29 patients who underwent autologous stem cell transplantation for hematologic malignancies, impairment of ovarian estrogen production was the only late endocrine toxicity. Bone mineral content was identical to that of the control group.

    25. Chemotherapy: Anemia
      You have free access to this content
      Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin (pages 1623–1628)

      Frank R. Dunphy, Teresa L. Dunleavy, Bruce R. Harrison, James H. Boyd, Mark A. Varvares, Cherie H. Dunphy, Jack J. Rodriguez, Erin M. McDonough, Jeffrey R. Minster and Murray D. McGrady

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1623::AID-CNCR28>3.0.CO;2-Z

      • original image

      When recombinant human erythropoietin was administered simultaneously with paclitaxel/carboplatin chemotherapy, it reduced anemia and the need for transfusions.

    26. Pediatric Oncology
      You have free access to this content
      Cytodifferentiation of a Wilms' tumor pulmonary metastasis : Theoretic and clinical implications (pages 1629–1634)

      Thomas A. Seemayer, James L. Harper, Derek Shickell and Thomas G. Gross

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1629::AID-CNCR29>3.0.CO;2-Z

      • original image
      • original image
      • original image
      • original image
      • original image

      This report suggests that therapy (chemotherapy and/or irradiation) may effect, on occasion, complete cytodifferentiation of Wilms' tumor pulmonary metastasis.

    27. Venous Access Devices in Cancer Patients
      You have free access to this content
      Subcutaneously implanted central venous access devices in cancer patients : A prospective analysis (pages 1635–1640)

      Roderich E. Schwarz, Jeffrey S. Groeger and Daniel G. Coit

      Version of Record online: 29 SEP 2000 | DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1635::AID-CNCR30>3.0.CO;2-X

      • original image
      • original image
      • original image
      • original image
      • original image

      This prospective series of 680 cancer patients who underwent placement of a subcutaneously implanted intravenous access device documented an overall complication rate of 14.5% and a 75% likelihood for patients to have a functional port in case of 3-year survival.

SEARCH

SEARCH BY CITATION